Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

468.80 -8.52 (-1.78%)
Streaming Delayed Price Updated: 9:45 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
71 72 Next >
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Technical Breakout Potential ↗
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Technical Breakout Potential 
Via Chartmill
News headline image
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount ↗
Via The Motley Fool
News headline image
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Earnings Scheduled For May 5, 2025 ↗
 
Via Benzinga
News headline image
5 Growth Stocks to Buy in May and Go Away ↗
Via The Motley Fool
Topics Artificial Intelligence Government World Trade
News headline image
Earnings To Watch: Vertex Pharmaceuticals (VRTX) Reports Q1 Results Tomorrow
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results tomorrow afternoon. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Earnings Outlook For Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
S&P Global, Berkshire Hathaway, CME Group And A Health Care Stock: CNBC's 'Final Trades' ↗
 
Via Benzinga
Topics Stocks
News headline image
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market ↗
Via The Motley Fool
Topics Artificial Intelligence Energy
News headline image
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday ↗
Via The Motley Fool
News headline image
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold ↗
Via The Motley Fool
Topics Government
News headline image
Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts ↗
 
Via Benzinga
News headline image
Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right ↗
Via The Motley Fool
Topics Economy Government World Trade
News headline image
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely ↗
Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and potential upside surprises. 
Via Benzinga
News headline image
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next ↗
Via The Motley Fool
Topics Government World Trade
News headline image
Peering Into Vertex Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
As The Nasdaq 100 Index Crashes, Is It Safe To Buy The Dip? ↗
The Nasdaq 100 Index remains under pressure after forming a death cross pattern a few weeks ago. It has retreated to $18,257, down by over 17.8% from its highest point this year. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
News headline image
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Government
News headline image
Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades ↗
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
News headline image
CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades' ↗
CrowdStrike has expanded its partnership with Google Cloud to enable end-to-end security for AI innovation. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗
Via The Motley Fool
News headline image
We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is. ↗
Via The Motley Fool
Topics Economy Government World Trade
News headline image
5 Top Growth Stocks to Buy in the Stock Market Sell-Off ↗
Via The Motley Fool
Topics Government
News headline image
Is Vertex Pharmaceuticals Stock a Buy? ↗
Via The Motley Fool
News headline image
These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue? ↗
A group of S&P 500 stocks have remained resilient as tariffs and earnings concerns cause the market to drop. Future gains may be limited. 
Via Benzinga
Topics Stocks World Trade
News headline image
Vertex to Announce First Quarter 2025 Financial Results on May 5th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers' ↗
Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.